IRIS
BRIGANTI, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 35.279
EU - Europa 32.977
NA - Nord America 28.229
SA - Sud America 10.511
Continente sconosciuto - Info sul continente non disponibili 1.210
AF - Africa 892
OC - Oceania 103
AN - Antartide 2
Totale 109.203
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.667
RU - Federazione Russa 18.712
SG - Singapore 12.952
CN - Cina 9.746
BR - Brasile 8.546
HK - Hong Kong 4.781
IT - Italia 4.448
SE - Svezia 3.693
VN - Vietnam 3.544
FR - Francia 1.814
BD - Bangladesh 1.090
DE - Germania 1.052
AR - Argentina 774
IN - India 660
CA - Canada 643
GB - Regno Unito 609
FI - Finlandia 541
ID - Indonesia 494
MX - Messico 386
NL - Olanda 357
EC - Ecuador 332
RO - Romania 286
IQ - Iraq 280
JP - Giappone 276
ES - Italia 264
ZA - Sudafrica 263
CO - Colombia 255
IE - Irlanda 244
TR - Turchia 235
PL - Polonia 190
AT - Austria 177
PY - Paraguay 149
PK - Pakistan 147
UA - Ucraina 133
CL - Cile 130
VE - Venezuela 130
MY - Malesia 121
MA - Marocco 114
JM - Giamaica 103
SA - Arabia Saudita 96
UZ - Uzbekistan 95
EG - Egitto 94
PE - Perù 92
CR - Costa Rica 85
NP - Nepal 85
AU - Australia 80
PH - Filippine 80
TN - Tunisia 75
AE - Emirati Arabi Uniti 74
KE - Kenya 72
IR - Iran 63
UY - Uruguay 59
LT - Lituania 58
DZ - Algeria 56
JO - Giordania 55
NG - Nigeria 54
DO - Repubblica Dominicana 47
HN - Honduras 47
IL - Israele 42
TT - Trinidad e Tobago 40
KZ - Kazakistan 39
NI - Nicaragua 38
AZ - Azerbaigian 37
CH - Svizzera 37
GT - Guatemala 37
AL - Albania 36
BE - Belgio 34
BO - Bolivia 32
SV - El Salvador 31
TH - Thailandia 31
GR - Grecia 30
KR - Corea 29
LB - Libano 29
BG - Bulgaria 28
PT - Portogallo 27
MD - Moldavia 26
TW - Taiwan 26
RS - Serbia 25
CZ - Repubblica Ceca 24
NO - Norvegia 22
OM - Oman 22
PA - Panama 22
PR - Porto Rico 21
SN - Senegal 21
BA - Bosnia-Erzegovina 20
BB - Barbados 19
BH - Bahrain 19
HU - Ungheria 18
TZ - Tanzania 17
KG - Kirghizistan 16
KH - Cambogia 16
PS - Palestinian Territory 15
NZ - Nuova Zelanda 14
AO - Angola 13
BY - Bielorussia 13
KW - Kuwait 13
SY - Repubblica araba siriana 13
CY - Cipro 12
ET - Etiopia 12
XK - ???statistics.table.value.countryCode.XK??? 12
Totale 107.733
Salva come PNG Salva come JPEG
Città #
Singapore 5.164
Hong Kong 4.720
Moscow 4.243
Dallas 4.192
San Jose 3.664
Ashburn 2.745
Council Bluffs 2.075
Shanghai 1.847
Hefei 1.801
Lawrence 1.710
Princeton 1.706
Lauterbourg 1.525
Ho Chi Minh City 1.325
Milan 901
Beijing 897
New York 877
Hanoi 747
Santa Clara 682
São Paulo 674
Los Angeles 511
Helsinki 412
Rome 343
Rio de Janeiro 264
Phoenix 241
Dublin 235
Boardman 218
Orem 196
Nuremberg 193
Munich 189
Belo Horizonte 185
Brooklyn 177
Da Nang 170
Chicago 167
Montreal 162
Brasília 159
Warsaw 147
Tokyo 143
Haiphong 136
Guangzhou 134
Atlanta 130
Denver 130
Turin 129
Naples 126
Porto Alegre 126
Johannesburg 124
Chennai 120
Curitiba 120
Houston 117
Mexico City 116
Frankfurt am Main 112
Toronto 108
Quito 106
Bologna 105
Seattle 105
Boston 103
Guayaquil 102
London 101
Salvador 97
Campinas 96
Baghdad 94
Turku 93
Tianjin 91
Stockholm 90
Buffalo 89
Washington 89
Biên Hòa 87
Florence 85
Tashkent 85
Thái Bình 85
Valencia 83
Guarulhos 80
Mumbai 80
Amsterdam 78
Hải Dương 78
Miami 78
Poplar 78
Ribeirão Preto 78
Manchester 77
Pune 76
Vienna 76
Dhaka 75
Manaus 72
Hangzhou 69
Kuala Lumpur 69
Philadelphia 69
Buenos Aires 66
Jakarta 66
San Francisco 66
Bogotá 64
Fortaleza 62
Lima 62
San José 62
The Dalles 61
Caxias do Sul 60
Paris 60
Columbus 59
Goiânia 58
Erbil 55
Brescia 54
Nairobi 54
Totale 51.163
Salva come PNG Salva come JPEG
Nome #
External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection 2.115
(11)C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms 1.443
Benign Prostatic Hyperplasia and Its Aetiologies 509
Women's sexual dysfunction: a pathophysiological review 319
Sexual dysfunction is common in women with lower urinary tract symptoms and urinary incontinence: Results of a cross-sectional study 267
Impact of prostate imaging quality (PI-QUAL) score on the detection of clinically significant prostate cancer at biopsy 262
Bladder cancer incidence rates and trends in young adults aged 20-39 years 262
A comparative review of apomorphine formulations for erectile dysfunction - Recommendations for use in the elderly 241
[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab 236
Indications for Pelvic Nodal Treatment in Prostate Cancer Should Change. Validation of the Roach Formula in a Large Extended Nodal Dissection Series 234
Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease 229
Pelvic/Retroperitoneal Salvage Lymph Node Dissection for Patients Treated With Radical Prostatectomy With Biochemical Recurrence and Nodal Recurrence Detected by [11C]Choline Positron Emission Tomography/Computed Tomography 202
Pelvic lymph node dissection in prostate cancer 195
11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy 195
[68Ga]Ga-PSMA and [68Ga]Ga-RM2 PET/MRI vs. Histopathological Images in Prostate Cancer: A New Workflow for Spatial Co-Registration 192
Updated Nomogram Predicting Lymph Node Invasion in Patients with Prostate Cancer Undergoing Extended Pelvic Lymph Node Dissection: The Essential Importance of Percentage of Positive Cores 187
[C-11]Choline PET/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy 186
A NOVEL MODEL INTEGRATING CLINICAL, MP-MRI, AND EPIGENOMIC FEATURES TO PREDICT LYMPH NODE INVASION IN PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY AND PELVIC LYMPH NODE DISSECTION 181
The Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence of Prostate Cancer After Definitive Treatment: A Systematic Review and Meta-analysis 180
11C-choline PET/CT predicts survival in prostate cancer patients with PSA < 1 NG/ml 177
A comprehensive assessment of frailty status on surgical, functional and oncologic outcomes in patients treated with partial nephrectomy––A large, retrospective, single-center study 174
Role of [68Ga]Ga-PSMA-11 PET radiomics to predict post-surgical ISUP grade in primary prostate cancer 168
Association between erectile dysfunction and coronary artery disease: Matching the right target with the right test in the right patient 167
[11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging 167
68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in Recurrent Prostate Cancer: Diagnostic Performance and Association with Clinical and Histopathological Data 166
A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02 164
Quantitative sensory testing of peripheral thresholds in patients with lifelong premature ejaculation: a case-controlled study 158
A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in patients with premature ejaculation 157
68Ga-PSMA-PET/CT Scan as Primary Staging for Prostate Cancer and Its Related Clinical Implications 156
A mechanistic insight into the anti-metastatic role of the prostate specific antigen 156
Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard 154
Lymphatic spread of nodal metastases in high-risk prostate cancer: The ascending pathway from the pelvis to the retroperitoneum 154
Does diabetes mellitus increase the risk of high-grade prostate cancer in patients undergoing radical prostatectomy? 152
[ 11C] Choline PET/CT Predicts Prostate Cancer-Specific Survival in Patients with Biochemical Failure During Androgen Deprivation Therapy 148
How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series 148
Accurate prediction of long-term risk of biochemical failure after salvage radiotherapy including the impact of pelvic node irradiation 147
Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review 146
Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer 145
11C-CHOLINE-POSITRON EMISSION TOMOGRAPHY/ COMPUTERISED TOMOGRAPHY FOR PREOPERATIVE LYMPH- NODE STAGING IN INTERMEDIATE-RISK AND HIGH-RISK PROSTATE CANCER: COMPARISON WITH CLINICAL STAGING NOMOGRAMS 145
120-MONTH MEDIAN FOLLOW-UP OF INTRACAVERNOUS INJECTION THERAPY FOR ERECTILE DYSFUNCTION 144
A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies 144
Holmium laser enucleation of the prostate versus open prostatectomy for prostates > 70 g: 24-month follow-up 143
Survival Effect of Nephroureterectomy in Metastatic Upper Urinary Tract Urothelial Carcinoma 143
[11C]CHOLINE PET/CT SCAN PREDICTS SURVIVAL IN PROSTATE CANCER PATIENTS WITH BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMY 141
Preoperative risk calculator for the probability of completing nephron sparing for kidney cancer 140
Assessing in-hospital morbidity after urethroplasty using the European Association of Urology Quality Criteria for standardized reporting 140
Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study 139
Neglected lymph nodal metastases in patients with renal cancer: when to extend the anatomical template of lymph node dissection during nephrectomy 138
A MINIMUM OF 14 CORES SHOULD BE TAKEN AT BIOPSY BEFORE PLANNING ACTIVE SURVEILLANCE FOR PATIENTS WITH LOW-RISK PROSTATE CANCER 138
A nomogram for staging of exclusive nonobturator lymph node metastases in men with localized prostate cancer 138
A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma 138
A propensity score approach for treatment evaluation based on Bayesian Networks 138
Holmium Laser Enucleation of the Prostate Is Associated with Complications and Sequelae Even in the Hands of an Experienced Surgeon Following Completion of the Learning Curve 136
Prediction of Functional Outcomes After Nerve-Sparing Radical Prostatectomy: Results of Conditional Survival Analyses 136
Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer 136
Accuracy of Transurethral Resection of the Bladder in Detecting Variant Histology of Bladder Cancer Compared with Radical Cystectomy 136
How to Select the Optimal Candidates for Renal Mass Biopsy 136
Contemporary Techniques of Prostate Dissection for Robot-assisted Prostatectomy 135
Acute Kidney Injury at Hospital Admission for SARS-CoV-2 Infection as a Marker of Poor Prognosis: Clinical Implications for Triage Risk Stratification 135
18F-FDG PET/CT and urothelial carcinoma: Impact on management and prognosis—a multicenter retrospective study 135
A CRITICAL APPRAISAL OF THE ABILITY OF BODY MASS INDEX (BMI) TO PREDICT HIGH-GRADE PROSTATE CANCER (PCA) 134
[C-11] Choline Positron Emission Tomography/Computerized Tomography for Early Detection of Prostate Cancer Recurrence in Patients with Low Increasing Prostate Specific Antigen 133
Age and gleason score upgrading between prostate biopsy and radical prostatectomy: Is this still true in the multiparametric resonance imaging era? 132
Impact of Early Dorsal Venous Complex Ligation on Urinary Continence Recovery after Robot-assisted Radical Prostatectomy: Results from a Phase 3 Randomized Controlled Trial 131
Time for action: actinium-225 PSMA-targeted alpha therapy for metastatic prostate cancer – a systematic review and meta-analysis 131
[11C]CHOLINE PET/CT for Early Detection of Tumor in Prostate Cancer Patients with PSA Level Lower Than 1.5 NG/ML 131
Identification of the Optimal Candidates for Nodal Staging with Extended Pelvic Lymph Node Dissection Among Prostate Cancer Patients Who Underwent Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography. External Validation of the Memorial Sloan Kettering Cancer Center and Briganti Nomograms and Development of a Novel Tool 130
ROBOT-ASSISTED RADICAL PROSTATECTOMY IS ASSOCIATED WITH FASTER AND GREATER RECOVERY FROM ORGASM ASSOCIATED INCONTINENCE 130
Preliminary results of an ongoing prospective clinical trial on the use of68ga-psma and68ga-dota-rm2 pet/mri in staging of high-risk prostate cancer patients 130
Use of 18F-fluoro-2-deoxy-d-glucose (18F-FDG) PET/CT for lymph node assessment before radical cystectomy in bladder cancer patients 129
Prostate-specific membrane antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a Prospective Phase 2 Study 129
Pembrolizumab in advanced renal cell carcinoma: a meta-analysis providing level 1a evidence 128
Clinical, pathological and long-term oncologic outcomes of papillary type I vs. type II renal cell carcinoma 128
Diagnostic accuracy of fully hybrid [68Ga]Ga-PSMA-11 PET/MRI and [68Ga]Ga-RM2 PET/MRI in patients with biochemically recurrent prostate cancer: a prospective single-center phase II clinical trial 128
Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer 127
Predictors of PSMA PET Positivity: Analysis in a Selected Cohort of Biochemical Recurrence Prostate Cancer Patients after Radical Prostatectomy 126
30-DAY MORTALITY AFTER RADICAL PROSTATECTOMY IN OVER 9000 PATIENTS: VALIDATION OF A PREDICTIVE NOMOGRAM 126
Upper Tract Urothelial Carcinoma in the Lynch Syndrome Tumour Spectrum: A Comprehensive Overview from the European Association of Urology - Young Academic Urologists and the Global Society of Rare Genitourinary Tumors 126
Defining the optimal target-to-background ratio to identify positive lymph nodes in prostate cancer patients undergoing robot-assisted [99mTc]Tc-PSMA radioguided surgery: updated results and ad interim analyses of a prospective phase II study 126
Does previous prostate surgery affect multiparametric magnetic resonance imaging accuracy in detecting clinically significant prostate cancer? Results from a single institution series 125
A critical analysis of Permixon (TM) in the treatment of lower urinary tract symptoms due to benign prostatic enlargement 125
Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis 125
Long-term functional outcomes in patients undergoing radical nephrectomy for renal cell carcinoma and tumor thrombus 124
A Head-to-head Comparison of Four Prognostic Models for Prediction of Lymph Node Invasion in African American and Caucasian Individuals 124
Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis 124
Impact of lymphovascular invasion on survival in surgically treated upper tract urothelial carcinoma: a nationwide analysis 123
How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most? 123
Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy 123
Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma 123
Radiomic and gEnomic approaches for the enhanced DIagnosis of clear cell REnal Cancer (REDIRECt): a translational pilot methodological study 122
Iron Induces Cell Death and Strengthens the Efficacy of Antiandrogen Therapy in Prostate Cancer Models 122
Impact of prostate MRI central review over the diagnostic performance of MRI-targeted biopsy: should we routinely ask for an expert second opinion? 121
MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis 121
Sexual function and endocrine profile in fertile women with type 1 diabetes 121
The impact of intraoperative bleeding on the risk of chronic kidney disease after nephron-sparing surgery 121
Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆ 121
Comparison between small renal masses 0-2 cm vs. 2.1-4 cm in size: A population-based study 121
Optimizing prostate-targeted biopsy schemes in men with multiple mpMRI visible lesions: should we target all suspicious areas? Results of a two institution series 121
Variability of mpMRI diagnostic performance according to the upfront individual patient risk of having clinically significant prostate cancer 120
Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinoma 120
Totale 18.718
Salva come PNG Salva come JPEG
Categoria #
all - tutte 748.938
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 748.938
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.023 0 0 34 464 59 58 95 67 33 60 43 110
2022/20238.177 3.959 1.455 485 70 52 804 299 457 256 84 137 119
2023/20243.865 149 210 328 296 295 574 217 373 84 317 466 556
2024/202521.927 3.053 565 362 531 501 1.789 2.790 1.624 4.142 3.496 1.417 1.657
2025/202665.753 4.408 5.874 6.280 10.073 4.204 1.508 5.649 4.231 16.295 3.266 1.882 2.083
2026/20277.649 2.538 4.122 989 0 0 0 0 0 0 0 0 0
Totale 109.203